Niagen Bioscience said NB4168 received FDA Rare Pediatric Disease designation and EMA Orphan Medicinal Product status for ataxia-telangiectasia. The dual backin

BWB News TV • 2026-07-22 15:11 UTC • By Billy Odell Tucker-Robinson

Niagen Bioscience said NB4168 received FDA Rare Pediatric Disease designation and EMA Orphan Medicinal Product status for ataxia-telangiectasia. The dual backing could unlock incentives including priority review and market exclusivity.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly